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Introduction: Overexpression of human epidermal growth factor 
receptor 2 (HER2) is found in about 20% of breast cancer 
patients. Trastuzumab has been widely used for the treatment 
of HER2 overexpressing breast cancer, but the incidence of 
brain metastases has increased due to its inherent limitation of 
crossing the blood-brain barrier (BBB). Thus, lapatinib, which 
has a low molecular weight and can cross the BBB, in 
combination with brain radiotherapy, will be a promising 
therapeutic strategy in the treatment of brain metastasis from 
HER2-positive breast cancer. 
Materials and Methods: To explore the impact of lapatinib on 
radiation response, we conducted an in vitro experiment using 
SKBR3 and BT474 breast carcinoma cells exhibiting HER2/neu 
amplification. Clonogenic assay and western blot was used to 
investigate the radiosensitivity of lapatinib. Antibody against 
γH2AX was used to detect DNA damage. Modes of cell death 
were assessed with V-FITC/propidium iodide double staining, 
β-galactosidase staining, and LysoTracker Green staining. 
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Results: Pretreatment of Lapatinib led down-regulation of p-
HER2, p-EGFR, p-AKT, and p-ERK. Lapatinib increased the 
radiosensitivity of SKBR3 (SER 1.21 at surviving fraction of 0.5) 
and BT474 (SER 1.26 at surviving fraction of 0.5) breast 
carcinoma cells, respectively. Lapatinib hindered repair of DNA 
damage as suggested by the prolongation of radiation-induced 
γH2AX foci and down-regulation of p-DNAPKcs. Increased 
radiation-induced apoptosis and senescence was suggested to 
be the major mode of cell death induced by lapatinib combined 
with radiation. Lapatinib didn’t increase radiation damage of 
normal human astrocytes. 
Conclusions: These findings suggest lapatinib potentiate 
radiation-induced cell killing in HER2-overexpressing breast 
cancer cells and could be a useful strategy to increase efficacy 
of radiotherapy. 
------------------------------------- 
Keywords: Breast cancer, Human epidermal growth factor 
receptor 2, Radiotherapy, Lapatinib 
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Overexpression of human epidermal growth factor receptor 2 
(HER2) is found in about 20% of breast cancer patients and is 
known to have a particularly aggressive natural history (1). In 
the last decade, the introduction of trastuzumab, an anti-HER2 
monoclonal antibody, has improved the survival of HER2-
positive patients dramatically when used in the adjuvant setting 
(2, 3). The addition of trastuzumab to neoadjuvant 
chemotherapy increases pathologic complete response rate and 
event-free survival in locally advanced breast cancer (4, 5). 
Even in metastatic breast cancer patients, trastuzumab 
improves response rate and survival (6, 7). However, the 
incidence of brain metastasis is significantly increased in 
HER2-positive breast cancer after treatment with trastuzumab, 
possibly due to the fact that trastuzumab enhances systemic 
control and prolongs survival, and thus clinically discloses brain 
metastasis (8). In HER2-positive metastatic breast cancer, 
despite receiving trastuzumab-based therapy, approximately 
30% of patients develop brain metastasis (9-11). Intracranial 
disease progression, rather than extracranial disease, is the 
3 
cause of death in about half of patients with brain metastasis (9, 
12). Therefore, in HER2-positive breast cancer patients with 
brain metastasis, control of intracranial disease is an important 
issue in terms of survival.  
Lapatinib ditosylate (GW572016/Tykerb®; GlaxoSmithKline, 
Research Triangle Park, NC) is a reversible dual inhibitor of the 
intracellular tyrosine kinase domain of HER1 and HER2. 
Lapatinib is expected to be used for breast cancer patients with 
brain metastasis because of its theoretical ability to cross the 
blood-brain barrier (BBB) resulting from its very low 
molecular weight (581 Da) (13). There has been attempts to 
demonstrate the effect of lapatinib for brain metastasis in 
patients with HER2-positive breast cancer, but the response 
rate of lapatinib alone to the brain lesions was only 3-6% (14-
20). 
We hypothesized that the combination of radiotherapy (RT) and 
lapatinib will be an effective strategy for HER2-positive breast 
cancer. Although there have been several in vitro studies using 
lapatinib alone or as a combination with other chemotherapeutic 
agents, no preceding in vitro studies are available on the 
4 
additive effect of lapatinib with RT (21, 22).  Recent in vivo 
study showed that more effective tumor regression could be 
achieved if lapatinib is used in combination with radiation (23). 
In this study, we investigated the radio-sensitizing effect of 
lapatinib using HER2-postivie breast cancer cell lines with 
clonogenic assay. Subsequently, we conducted in vitro 
experiments identifying the modes of cell death by lapatinib and 
radiation. We also checked whether the lapatinib has a harmful 
effect on normal human brain cells. 
  
5 
MATERIALS AND METHODS 
1. Cell lines and cell culture 
We used two HER2 amplified breast cancer cell lines (SKBR3 
and BT474, American Type Culture Collection, Rockville, MD) 
(24). Cells were grown in 75 cm2 plastic tissue culture flasks at 
37°C in Dulbeco ’ s modified Eagle ’ s medium (DMEM, 
Welgene, Daegu, Korea) containing 10% fetal bovine serum 
(FBS; Invitrogen, Carlsbad, CA, USA) in 5% CO2. Immortalized 
normal human astrocytes (NHAs) were derived from fetal 
brains. 
 
2. Pharmacologic inhibitor 
Lapatinib ditosylate (GW572016/Tykerb®; GlaxoSmithKline, 
Research Triangle Park, NC, USA) is a dual tyrosine kinase 
inhibitor of the HER1 (also known as epidermal growth factor 
receptor, EGFR) and HER2 domain (25). Lapatinib ditosylate 
was dissolved into concentrated stock solutions in DMSO, 
stored at -20°C, and diluted at the time of use in culture 
medium. Control cells were treated with medium containing an 
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equal concentration of the drug carrier, DMSO. 
In a study by Taskar et al, lapatinib was administered (100 
mg/kg, 200μL per mouse) to mice via oral gavage. At 2 hours 
after oral administration, blood lapatinib concentration was 5.59
±0.56 μM and lapatinib concentration from metastatic brain 
tissue was 0.71±0.61 μM (21). 
Morikawa, et al. conducted a prospective study in patients with 
brain metastases from breast cancer. The patients received 
1250mg of oral lapatinib daily for 2-5 days. At the time of 
brain tumor resection, serum lapatinib concentration was 2.4-
6.5mcM and lapatinib concentration from metastatic brain tissue 
was 1-63.6mcM. (26). However, tissue concentrations are not 
significant as reference points, due to the variability and 
unpredictability of the BBB in brain metastasis. Thus, with 
reference to previous data using serum lapatinib concentration, 
we decided on 5μM of lapatinib as our reference point. 
 
3. Clonogenic assays 
Equal numbers of cells were plated across the different 
7 
treatment groups for each radiation dose. A specified number of 
cells was seeded into each well of six-well culture plates and 
treated with lapatinib two hours before irradiation. The cells 
were irradiated with 4-MV x-rays from a linear accelerator 
(Clinac 4/100, Varian Medical Systems, Palo Alto, CA, USA) at 
a dose rate of 2.46 Gy/min and were incubated for 14–21 days 
for colony formation. Colonies were fixed with methanol and 
stained with 0.5% crystal violet. The number of colonies 
containing at least 50 cells was determined, and the surviving 
fraction was calculated. Radiation survival data were fitted to a 
linear-quadratic model using Kaleidagraph version 3.51 
(Synergy Software, Reading, PA, USA). Each point on the 
survival curves represents the mean surviving fraction from at 
least three dishes. The sensitizer enhancement ratio (SER) was 
calculated as the ratio of the isoeffective dose at a surviving 
fraction of 0.5 in the absence of lapatinib to that in the presence 
of lapatinib. 
 
4. Western blot analysis 
Cells were washed, scraped, and resuspended in lysis buffer 
8 
(iNtRON Biotechnology, Seoul, Korea). Proteins were 
solubilized by sonication, and equal amounts of protein were 
separated on SDS-PAGE and electroblotted onto 
polyvinylidene difluoride membranes (Millipore Corp., Bedford, 
MA, USA). Membranes were blocked in PBS containing 0.1% 
Tween 20 and 5% powdered milk, and probed with primary 
antibody directed against p-HER2 (Tyr1221/1222), p-EGFR 
(Tyr1068), p-AKT (Ser473), p-ERK (Tyr202/204), p-
DNA-PKs (Thr2609), Rad51, caspase3, and LC3 (Cell 
Signaling Technology, Inc.). Monoclonal anti-β-actin antibody 
was used at a 1:5,000 dilution (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). Membranes were washed and incubated with a 
secondary antibody consisting of peroxidase-conjugated goat 
anti-rabbit or anti-mouse immunoglobulin G (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA) at a 
dilution of 1:2,000 for one hour. Antibody binding was detected 
using an enhanced chemiluminescence detection kit (Amersham 
Biosciences, Piscataway, NJ, USA) using the appropriate 




Cells were grown and treated on chamber slides. At specified 
times after treatment with lapatinib and/or radiation, cover-
slips were rinsed, and cells were fixed in 4% paraformaldehyde 
and permeabilized in methanol for 20 minutes. Cells were 
subsequently washed and blocked in PBS containing 2% bovine 
serum albumin for one hour. A primary antibody against γ
H2AX (Cell Signaling Technology, Inc.) was applied to the cells 
and incubated overnight. Secondary fluorescein isothiocyanate 
(FITC) anti-rabbit antibody (Molecular Probes, Eugene, OR, 
USA) was applied and incubated for two hours. A 4′,6-
Diamidino-2-phenylindole (DAPI) nuclear counter stain was 
applied at 1 μg/mL for five minutes.  
For analysis of autophagy, cells were washed and subsequently 
stained with 1 mM LysoTracker® Green (Molecular Probes) 
diluted in PBS for 10 minutes at 24 hours after irradiation. 
Apoptosis was evaluated using annexin V-FITC/propidium 
iodide (PI) double staining. Slides were examined on an Axio 
Scope.A1 Imager fluorescent microscope. Images were 
captured and acquired using AxioCam MRc5 and the acquisition 
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software AxioVision v.4.4 (Carl Zeiss, Gottingen, Germany). 
The number of formation of γH2AX foci was counted under 
100x power field and the number of Punta in a cell was counted 
under 400x power field. 
 
6. Senescence β-galactosidase staining 
Cellular senescence was evaluated by detecting the activity of 
β-galactosidase. Tumor cells were seeded in 8-well chamber 
slides, treated with lapatinib and/or irradiation, and then stained 
using a Senescence β-Galactosidase Staining Kit (Cell 
Signaling Technology, Inc.) according to the manufacturer’s 
instructions. Cells were examined using a light microscope. The 
number of cells stained by β-galactosidase was counted under 
100x power field. 
 
7. Modified Boyden chamber assay 
Cell invasion was assessed using a Transwell System (Corning, 
Rochester, NY, USA) that allows cells to migrate through 8-
mm pores in polycarbonate membranes. The membranes were 
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coated with a 10-mg/well gelatin solution in DMEM without 
FBS and dried. Inserts containing cells were placed into 24-
well plates in starvation medium. Cells were trypsinized, 
washed, and resuspended (5×106 cells/mL) in starvation 
medium. An aliquot of 106 cells was added to the upper 
chamber. The lower chamber was filled with 500 mL of DMEM 
without FBS. After 24 hours, the surface of the upper 
membrane was swabbed with a cotton-tipped applicator to 
remove non-invasive cells. Inserts were fixed in methanol for 
10 minutes and stained with 1 crystal violet for two hours. The 
invasion rate was quantitated microscopically by counting the 
number of moved cells. 
 
8. Statistical analysis 
Data were analyzed for descriptive statistics using SPSS 
software (SPSS Inc, Chicago, IL, USA). The independent t-test 
was used to evaluate differences of each variable. A p value < 




1. Lapatinib radio-sensitizes breast cancer cells 
overexpressing HER2. 
To explore the impact of lapatinib on the radiation response, 
SKBR3 and BT474 breast carcinoma cells exhibiting HER2/neu 
amplification were treated with DMSO or lapatinib (5 μM). 
Lapatinib resulted in down-regulation of p-HER2, p-EGFR, 
and p-ERK (Figure 1, A and B). This was associated with 
increased radiosensitivity of SKBR3 and BT474 cells, as shown 
by decreased cell survival (Figure 1). The SER of lapatinib at a 
surviving fraction of 0.5 and 0.05 in SKBR3 cells was 1.21 and 
1.11, respectively, and in BK474 cells was 1.258 and 1.279, 
respectively. Therefore, we concluded that lapatinib increases 




Figure 1. Lapatinib radio-sensitized breast cancer cells 
overexpressing HER2. 
 
(A) SKBR3 cells were treated with different concentration of 
lapatinib and the cell extracts were Western blotted with the 
indicated antibodies. Lapatinib attenuated the expression of p-
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HER2, p-EGFR, p-AKT, and p-ERK in SKBR3 cells. The 
SKBR3 cells were treated with either DMSO or lapatinib (5 μM) 
and irradiated with 4-MV x-rays. The surviving fraction of 
cells treated with lapatinib was lower than that of control group.  
(B) BT474 cells were treated with different concentration of 
lapatinib and the cell extracts were Western blotted with the 
indicated antibodies. Lapatinib attenuated the expression of p-
HER2, p-EGFR, p-AKT, and p-ERK in BT474 cells. The 
BT474 cells were treated with either DMSO or lapatinib and 
irradiated with 4-MV x-rays. The surviving fraction of cells 
treated with lapatinib was lower than that of control group. *P≤




2. Lapatinib hinders repair of DNA damage and may be 
involved in non-homologous end-joint repair. 
Lapatinib caused marked increase of radiation-induced γH2AX 
foci indicating delayed repair of DNA damage compared to the 
control (Figure 2, A and B). To elucidate which repair 
mechanism is associated with the impact of lapatinib, whole cell 
extracts were Western blotted with p-DNAPK, Rad51, and β-
actin. The expression of p-DNAPKcs, which is involved in 
non-homologous end-joining repair, was downregulated. 
Rad51, which indicates homologous recombination repair, was 
not affected by lapatinib. Thus, lapatinib hampers repair of DNA 







Figure 2. DNA damage repair: Lapatinib induced increase of γ
H2AX foci. 
(A) SKBR cells were treated with DMSO or Lapatinib (5μM). 
The degree of DNA damage repair then determined by number 
of formation of γH2AX foci 3 hours following 6 Gy of radiation. 
Lapatinib led increase of γH2AX foci formation (P=0.001). 
The whole cell extracts were Western blotted with p-DNAPK, 
Rad51 and β-actin. The expression of p-DNA-PKcs was 




(B) BT474 cells were treated with DMSO or Lapatinib (5μM). 
The degree of DNA damage repair then determined by number 
of formation of γH2AX foci 3 hours following 6 Gy of radiation. 
Lapatinib led increase of γH2AX foci formation (P=0.038). 
The whole cell extracts were Western blotted with p-DNAPK, 
Rad51 and β-actin. The expression of p-DNA-PKcs was 




3. Lapatinib potentiates radiation-induced apoptosis and 
senescence. 
We next asked which mechanisms of cell killing would affect 
the cell’s radiosensitivity to lapatinib. To this end, SKBR3 
cells were treated with DMSO, lapatinib (5 μM), radiation (6 
Gy), or lapatinib (5 μM) and radiation (6 Gy), and then stained 
with PI and antibodies against annexin V (Figure 3A). The 
number of apoptotic cells was then determined by double 
stained foci with annexin V and PI. Radiation alone and lapatinib 
alone did not appreciably increase apoptosis, but a significant 
increase in apoptosis was observed when they were used 
concurrently. Western blot using whole cell extracts also 
showed increased apoptosis when lapatinib was used in addition 
to radiation. Senescence was examined by detecting the activity 
of β-galactosidase and a notable change was observed in the 
cells treated with both radiation and lapatinib (Figure 3B). Thus, 
based on these assays, lapatinib induces both apoptosis and 





Figure 3. Lapatinib potentiated radiation-induced apoptosis and 
senescence.  
(A) SKBR cells were treated with lapatinib (5 μM), radiation 
(6 Gy), or lapatinib (5 μM) and radiation (6 Gy), then stained 
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with PI and antibodies against annexin V. The number of 
apoptotic cells was determined by double stained foci with 
annexin V and PI. The number of apoptotic cells was highest in 
the cells treated with both lapatinib and radiation. The whole 
cell extracts were Western blotted with the indicated antibodies 






(B) Senecence was examined by detecting the activity of β-
galactosidase and notable change was observed in the cells 





(C) SKBR cells were treated with lapatinib (5 μM), radiation 
(6 Gy), or lapatinib (5 μM) and radiation (6 Gy), then stained 
with LysoTracker® Green for 10 minutes. The number of Punta 
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formation in the cells treated with radiation and lapatinib was 
higher than any other cell groups, but it was not statistically 
significant compared to the cells with either lapatinib or 
radiation. The whole cell extracts were Western blotted with 
the indicated antibodies and the expression of LC3 was 





4. Autophagy does not significantly increase after the 
addition of lapatinib to cells treated with radiation alone. 
To analyze autophagy, cells were stained with LysoTracker® 
Green for 10 minutes. Lysosomal localization was significantly 
higher in cells treated with lapatinib and radiation compared 
with the control, but there was no significant difference 
between cells treated with either lapatinib or radiation and 
those treated with both lapatinib and radiation (Figure 3C). 
Thus, based on this assay, in our hands, lapatinib does not 
potentiate radiation-induced autophagy. 
 
5. Lapatinib does not affect radiosensitivity of normal 
human brain cells. 
To examine the effect of lapatinib on normal human brain cells, 
NHAs treated with either DMSO or lapatinib were used. 
Lapatinib led down-regulated p-HER2 and p-EGFR (Figure 4). 
Lapatinib did not appear to increase radiosensitivity of NHAs in 
the clonogenic assay, and the SERs of the isoeffective dose at 
surviving fractions 0.5 and 0.05 were 1.0. Therefore, based on 
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this assay, lapatinib has little effect on human normal brain cells 
in contrast with breast cancer cell lines overexpressing HER2. 
 
 
Figure 4. Lapatinib doesn’t affect radiosensitivity of NHAs.  
NHAs were treated with different concentration of lapatinib and 
the cell extracts were western blotted with the indicated 
antibodies. Lapatinib attenuated the expression of p-HER2 and 
p-EGFR in NHAs. The NHAs were treated with either DMSO 
or lapatinib and irradiated with 4-MV x-rays. Lapatinib did not 




Lapatinib is expected to be used for breast cancer patients with 
brain metastasis because of its theoretical ability to cross the 
BBB resulting from its very low molecular weight (581 Da) 
(13). Lapatinib is the first HER2-targeting drug that has been 
identified in a preclinical study to have activity against the brain 
metastasis of breast cancer. When EGFR-overexpressing 
MDA-MB-231-BR (231-BR-HER2) brain-seeking breast 
cancer cells were injected in a mouse model, metastatic 
colonization in mouse brains was inhibited by 50–53% in 
response to lapatinib (22). Subsequently, concentrations of 
radioactively labeled lapatinib were validated in mice with 231-
BR-HER2 brain-seeking breast cancer cells. The 
concentration found in the brain metastasis was 7–9 folds 
higher than in normal brain tissue; however, it was much lower 
than in peripheral metastasis (only 10–20% according to the 
time from lapatinib administration) (27).  
Lapatinib alone for brain metastasis in patients with HER2-
positive breast cancer demonstrated limited potential following 
prior RT as shown in Table 1 (14-20). Lin, et al. (14) 
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conducted a phase II trial for patients with HER2-positive 
breast cancer, brain metastasis, and prior trastuzumab 
treatment. The results were disappointing: no patients achieved 
a complete response (CR) and only one patient had a partial 
response (PR). In a subsequent expanded study with 242 
patients, 15 patients (6%) achieved an objective response 
(defined as ≥50% volume reduction in brain metastases). For 
patients with disease progression on single-agent lapatinib, the 
option of additional capecitabine was allowed. In these patients, 
objective response was observed in 10 (20%) of 50 patients 
(15). Similarly, Sutherland, et al. (16) reported a response rate 
of 21% in 34 patients with brain metastasis who had been 
administered lapatinib and capecitabine. Since almost patients in 
these lapatinib trials underwent RT to the brain before 
enrollment, a potential delayed effect of RT may confuse the 
cytotoxic effect of lapatinib. In contrast, Bachelot, et al. (18) 
excluded patients previously treated with WBRT (whole brain 
radiotherapy), capecitabine, or lapatinib. Among 44 patients 
assessable for efficacy, 29 patients (66%) achieved ≥50% 
volume reduction in brain metastases after treatment with 
lapatinib and capecitabine. 
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Table 1. Prospective trials on lapatinib without brain radiotherapy for brain metastases 






PFS, median OS, median 
de Azambuja, 
et al. (17) 




L+Tm CR 0 (0%) 
PR 0 (0%) 
2.6 M 10.9 M 
Bachelot, et al. 
(18)  
II 45 42 No L+C CR 2 (5%) 
PR 22 (52%) 
OR
*
 29 (66%) 
TTP, 5.5 M 17 M 
Iwata, et al. 
(19) 




Not reported Not reported 







CR 0 (0%) 
PR
*
 5 (38%) 
CR 0 (0%) 
PR
*
 0 (0%) 
Not reported Not reported 
Sutherland, et 
al. (16) 
 34 All WBRT (94%) 
 
L+C CR 1 (3%) 
PR 6 (18%) 
TTP, 22 W Not reported 








CR 0 (0%) 
PR
*












Lin, et al. (14) II 39 All WBRT 20 
SRS 6 
WBRT+SRS 11 
L CR 0 (0%) 
PR 1 (3%) 
TTP, 3 M Not reported 
*
 Partial response was defined as ≥50% volume reduction. 
†
 Patients with disease progression on single-agent lapatinib were given the option to receive the combination of lapatinib plus 
capecitabine.  
Abbreviations: L, lapatinib; Tm, temozolomide; C, capecitabine; To, topotecan; WBRT, whole brain radiotherapy; SRS, radiosurgery; 
RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; OR, overall response; PFS, 
progression-free survival; TTP, time to progression; OS, overall survival; M, month; W, week.  
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Lapatinib has been shown to have a radiosensitizing effect in a 
preclinical breast cancer model. Sambade, et al. (23) reported 
in vivo data in which mice bearing xenografts of basal-
like/EGFR-positive SUM149 and HER2-positive SUM225 
breast cancer cells were treated with lapatinib and fractionated 
RT. The treatment with lapatinib alone had no influence on 
tumor growth for basal-like/EGFR+ SUM149 breast cancer 
tumors; however, it provided significant tumor volume reduction 
for HER2+ SUM225 breast cancer tumors. After the 
combination of lapatinib plus RT, mouse tumor volumes were 
significantly reduced in both the basal-like/EGFR+ SUM149 
model and the HER2+ SUM225 model. During the study 
duration, treatment with both lapatinib and RT resulted in an 
average enhancement ratio of 1.25 for the HER2+ SUM225 
model. According to immunohistochemical analyses, the 
radiosensitizing effect of lapatinib was associated with inhibition 
of AKT in the HER2+ SUM225 model. The radio-sensitizing 
effect of lapatinib was also demonstrated in our in vitro 
experiment. Furthermore, we could assume that lapatinib 
increases the radio-sensitivity by decreasing delayed repair of 
DNA damage via down-regulating non-homologous end-
30 
joining repair, and increasing radiation-induced apoptosis and 
senescence.  
There is only one clinical trial reporting the combination of 
lapatinib and WBRT, a phase I study for 35 patients with brain 
metastasis of HER2-positive breast cancer (28). Lapatinib 
750mg was administered twice on the first day, followed by 
1000, 1250, or 1500 mg once daily. WBRT (37.5 Gy in 15 
fractions over three weeks) was started in the first eight days 
after the administration of lapatinib. During WBRT, patients 
received lapatinib continuously. After the completion of WBRT, 
patients were given 2 mg/kg of trastuzumab every week, 
combined with 1000 mg of lapatinib every day. Among 28 
patients who had measurable brain lesions at baseline, the 
response rate was 79% (CR in three patients and PR in 19 
patients) according to RECIST criteria. With a median follow-
up time of 3.8 years, the median PFS and survival times were 
4.8 and 19 months, respectively. Although, this study was 
designed to define the maximum tolerated dose of lapatinib and 
did not accomplish the primary goal due to toxicity, a high rate 
of CNS response was observed, indicating that lapatinib could 
be a good radiosensitizer in brain metastasis patients with 
31 
HER2-positive breast cancer. 
Based on these in vitro, in vivo and clinical evidences 
supporting the radiosensitizing effect of lapatinib, several 
clinical trials are currently underway to elucidate the effect of 
lapatinib with radiation. The Radiation Therapy Oncology Group 
is performing a phase II randomized study on breast metastases 
in HER-positive breast cancer. Patients in the study are 
randomly assigned to receive WBRT with or without lapatinib. 
Lapatinib will be given 1000 mg orally once daily. Lapatinib will 
be started on the first day of WBRT and continue throughout 
WBRT and 21 days after the final day of WBRT without a drug 
holiday. The complete response rate in the brain will be 
assessed by a brain magnetic resonance imaging scan at 12 
weeks post WBRT. 
Recently, Stanford University initiated a phase II trial 
investigating the efficacy of lapatinib and RT in patients with 
locally advanced or locally recurrent breast cancer. Patients 
will receive lapatinib once daily starting seven days before RT 
until completion of RT. Response rates will be assessed after 
the treatment. The Hellenic Cooperative Oncology Group has 
32 
designed a phase II trial to evaluate the response rate of brain 
metastases from lung and breast tumors under treatment with 
WBRT and lapatinib. This study is a single-arm study and in 
which patients will be treated with WBRT (30 Gy in 10 
fractions) and lapatinib 1250 mg once daily, followed by 





Lapatinib increases radiosensitivity of the HER2-postive breast 
cancer cells without effect to normal human astrocytes. 
Lapatinib hinders repair of DNA damage which probably relates 
with non-homologous end-joining repair. The cell killing effect 
of lapatinib may be related to increase radiation-induced 
apoptosis and senescence, rather than autophagy. At this time, 
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배경: 인간표피성장인자2(HER2)의 과발현은 유방암 환자의 20% 
정도에서 발견된다. 트라스트주맙은 HER2 과발현 유방암에서 
효과적인 치료법으로써 널리 이용되고 있지만, 혈액 뇌관문을 
통과하지 못하는 제한점 때문에 오히려 뇌전이의 발생은 증가했다. 
라파티닙은 분자량이 작아 혈액 뇌관문을 통과할 수 있어 
전뇌방사선치료와 혼합하는 것이 HER2 과발현 유방암의 뇌전이 
치료에 유망한 치료 전략이 될 것이다. 
대상환자 및 방법: HER2 과발현된 유방암에서 라파티닙의 방사선 
반응성에 대한 효과를 알아보기 위해, HER2/neu 유전자가 
증폭되어 나타나는 유방암 세포인 SKBR3와 BT474에 라파티닙을 
처리하여 세포주 실험을 시행하였다. 라파티닙의 방사선민감도를 
알아보기 위해 클론원성 분석과 웨스턴블롯 분석을 이용하였고, 
DNA 손상을 감지하기 위해 γH2AX에 대한 항체를 이용하였다. 
세포사 유형은 V-FITC/propidium iodide 이중염색과 β-
galactosidase 염색, LysoTracker Green 염색을 통해 평가하였다. 
결과: 라파티닙은 SKBR3와 BT474 세포의 p-HER2, p-EGFR, 
p-AKT, p-ERK의 발현을 감소시켰고, SKBR3와 BT474 세포의 
42 
방사선민감도를 증가시켰다 (SKBR3, 생존분율 0.5에서 SER 1.21; 
BT474, 생존분율 0.5에서 SER 1.26). 라파티닙은 방사선 유도하 
γH2AX의 증가와 p-DNAPKc의 하향조절됨을 통해 DNA 손상의 
수리를 저해하였음을 알 수 있었다. 또한 이러한 라파티닙과 
방사선의 혼합으로 유도되는 세포사의 기전은 자가포식 보다는 
방사선 유도 세포 자멸과 노화와 관계되었다. 라파티닙은 정상 인간 
별아교세포의 방사선 손상은 증가시키지 않았다. 
결론: 이러한 결과는 HER2 양성인 유방암 세포에 대한 방사선 
민감도 효과를 보여주었고 향후 유방암 치료에 있어 방사선치료와 
함께 라파티닙을 잠재적으로 응용해볼 수 있을 것이다. 
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